TY - JOUR
T1 - Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
AU - Mofaz, Merav
AU - Yechezkel, Matan
AU - Guan, Grace
AU - Brandeau, Margaret L.
AU - Patalon, Tal
AU - Gazit, Sivan
AU - Yamin, Dan
AU - Shmueli, Erez
N1 - Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfizer-BioNTech, https://www.pfizer. com) vaccine dose. A total of 1,609 participants were equipped with smartwatches and completed daily questionnaires through a dedicated mobile application. The extent of systemic reactions reported after the booster dose was similar to that of the second dose and considerably greater than that of the first dose. Analyses of objective heart rate and heart rate variability measures recorded by smartwatches further supported this finding. Subjective and objective reactions after the booster dose were more apparent in younger participants and in participants who did not have underlying medical conditions. Our findings further support the safety of the booster dose from subjective and objective perspectives and underscore the need for integrating wearables in clinical trials.
AB - Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfizer-BioNTech, https://www.pfizer. com) vaccine dose. A total of 1,609 participants were equipped with smartwatches and completed daily questionnaires through a dedicated mobile application. The extent of systemic reactions reported after the booster dose was similar to that of the second dose and considerably greater than that of the first dose. Analyses of objective heart rate and heart rate variability measures recorded by smartwatches further supported this finding. Subjective and objective reactions after the booster dose were more apparent in younger participants and in participants who did not have underlying medical conditions. Our findings further support the safety of the booster dose from subjective and objective perspectives and underscore the need for integrating wearables in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85132455644&partnerID=8YFLogxK
U2 - 10.3201/eid2807.212330
DO - 10.3201/eid2807.212330
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35654410
AN - SCOPUS:85132455644
SN - 1080-6040
VL - 28
SP - 1375
EP - 1383
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 7
ER -
